olfactory receptor family 10 subfamily A member 5Genealiases: JCG6 · OR10A1 · OR11-403
Q-omics provides the consensus-scored OR10A5 profile across patient tissues and cancer cell-line models. OR10A5 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, OR10A5 is differentially expressed in 1, with the highest sampling consensus in UCEC. Additionally, OR10A5 RNA expression shows 8,048 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight STAD, UCEC, and KIRP as cancer lineages where OR10A5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR10A5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR10A5 survival associations across molecular data types. OR10A5 RNA expression shows survival associations in the most cancer types (10), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR10A5 RNA expression–survival associations across cancer types. High OR10A5 expression shows unfavorable associations in STAD, THCA, CESC, OV and THYM, but favorable associations in ESCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for OR10A5 RNA expression.
This table summarizes OR10A5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for OR10A5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR10A5 shows higher tumor expression in UCEC. The UCEC box plot shows higher OR10A5 RNA expression in tumor versus normal tissue (log2 FC = +0.027, t-test p = .045).
This table shows molecular features associated with OR10A5 in patient tissues and cancer cell lines. In patient samples, OR10A5 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, OR10A5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
